The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer

被引：6
|
作者：
Al-Rawi, Duaa H. [1 ,2 ]
Rusk, Nicole [2 ]
Friedman, Claire F. [1 ,3 ,4 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Computat Oncol, New York, NY USA
[3] Weill Cornell Med Coll, Dept Med, New York, NY USA
[4] 300 East 66th Str,Room 1349, New York, NY 10065 USA
来源：
CLINICAL CANCER RESEARCH | 2023年 / 29卷 / 09期
基金：
美国国家卫生研究院;
关键词：
BEVACIZUMAB;
D O I：
10.1158/1078-0432.CCR-23-0048
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immune checkpoint blockade has been ineffective in ovarian cancer, and there is an ongoing effort to identify biomarkers of therapeutic benefit. Despite promising preclinical data, a substudy of the IMagyn050 trial found that patients with homologous recombination deficient tumors did not have improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab. See related article by Landen et al., p. 1698
引用
收藏
页码：1645 / 1647
页数：3
相关论文
共 50 条
  • [21] Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers
    Ros, Javier
    Baraibar, Iosune
    Saoudi, Nadia
    Rodriguez, Marta
    Salva, Francesc
    Tabernero, Josep
    Elez, Elena
    CANCERS, 2023, 15 (17)
  • [22] Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
    Vanderstichele, Adriaan
    Busschaert, Pieter
    Olbrecht, Siel
    Lambrechts, Diether
    Vergote, Ignace
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 5 - 14
  • [23] Genomic predictors of ovarian cancer response to salvage therapy
    Cragun, J.
    Xiong, Y.
    Boren, T. P.
    Indermaur, M. D.
    Sayer, R.
    Humphrey, M. M.
    Cottrill, H. M.
    Kamath, S.
    Hakam, A.
    Apte, S. M.
    Wenham, R. M.
    Berchuck, A.
    Lancaster, J. M.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S133 - S133
  • [24] Candidate biomarkers and treatment response predictors for ovarian cancer
    Gagnon, A.
    Bandera, C. C.
    Mok, S. C.
    MOLECULAR & CELLULAR PROTEOMICS, 2006, 5 (10) : S19 - S19
  • [25] Biomarkers for ovarian cancer and the host response amplification cascade
    Fung, Eric T.
    TUMOR BIOLOGY, 2006, 27 : 12 - 12
  • [26] Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer
    Zang, Yuan-sheng
    Dai, Chun
    Xu, Xiaoman
    Cai, Xin
    Wang, Guan
    Wei, Jinwang
    Wu, Angela
    Sun, Wending
    Jiao, Shunchang
    Xu, Qiang
    CANCER MEDICINE, 2019, 8 (10): : 4699 - 4708
  • [27] Novel biomarkers for prognosis and therapy response in ovarian cancer
    Diamandis, E. P.
    EJC SUPPLEMENTS, 2007, 5 (08): : 13 - 13
  • [28] Biomarkers in Cancer Immunotherapy
    Schumacher, Ton N.
    Kesmir, Can
    van Buuren, Marit M.
    CANCER CELL, 2015, 27 (01) : 12 - 14
  • [29] Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
    Trebeschi, S.
    Drago, S. G.
    Birkbak, N. J.
    Kurilova, I
    Calin, A. M.
    Pizzi, A. Delli
    Lalezari, F.
    Lambregts, D. M. J.
    Rohaan, M. W.
    Parmar, C.
    Rozeman, E. A.
    Hartemink, K. J.
    Swanton, C.
    Haanen, J. B. A. G.
    Blank, C. U.
    Smit, E. F.
    Beets-Tan, R. G. H.
    Aerts, H. J. W. L.
    ANNALS OF ONCOLOGY, 2019, 30 (06) : 998 - 1004
  • [30] Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
    Raimondi, Alessandra
    Sepe, Pierangela
    Zattarin, Emma
    Mennitto, Alessia
    Stellato, Marco
    Claps, Melanie
    Guadalupi, Valentina
    Verzoni, Elena
    de Braud, Filippo
    Procopio, Giuseppe
    FRONTIERS IN ONCOLOGY, 2020, 10
12345